Relatively-subdued COVID-19 fears
23/03/20 -"With aggravating COVID-19 fears and a material effect on the pharma supply chain – especially with respect to APIs, other than already known biosimilar risks, near-term earnings pressure is ..."
Pages
67
Language
English
Published on
23/03/20
You may also be interested by these reports :
23/02/26
Factoring in the SIFI acquisition (worth nearly 17% of Faes’ current market cap) and Faes Farma’s healthy (+16% topline growth in 9M 25) operating ...
20/02/26
After incorporating the 2025 financials, we have added a new forecast year to our model, which expects a continuation of growth at Novartis. The firm ...
20/02/26
Expanding margins despite moderate topline growth
18/02/26
After Bayer announced that it will settle most of the Roundup (glyphosate; herbicide) related class action suits (alleging Non-Hodgkin’s lymphoma, a ...